University of Leeds
AZD1390(University of Leeds)은 Non Small Cell Lung Cancer 표적 치료제로, Non Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting TAT-activated and survival-promoting signaling pathway. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 9건의 관련 임상이 등록되어 있습니다. 차별점: novel strategies to increase the efficacy of CLM-based ADCs such as GO and InO.
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Recruiting
gene therapy, cell engineering, and other applications
Calicheamicin-Based Antibody-Drug Conjugates for Acut
AAV-Induced Activation of Apoptotic Pathways
novel strategies to increase the efficacy of CLM-based ADCs such as GO and InO
targeting TAT-activated and survival-promoting signaling pathway
T cells, the MDM2 inhibitor and p53 activator, idasanutlin, enhanced CLM cytotoxicity
DNA damage response is considered an important strategy to enhance tumour cell killing caused by radiotherapy
biomarkers and therapeutic targets informing precision medicine strategies for PBT are mostly missing
resistance mechanisms to GO/InO remain incompletely understood
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
University of Leeds
AZD1390(University of Leeds)은 Non Small Cell Lung Cancer 표적 치료제로, Non Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting TAT-activated and survival-promoting signaling pathway. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 9건의 관련 임상이 등록되어 있습니다. 차별점: novel strategies to increase the efficacy of CLM-based ADCs such as GO and InO.
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Recruiting
gene therapy, cell engineering, and other applications
Calicheamicin-Based Antibody-Drug Conjugates for Acut
AAV-Induced Activation of Apoptotic Pathways
novel strategies to increase the efficacy of CLM-based ADCs such as GO and InO
targeting TAT-activated and survival-promoting signaling pathway
T cells, the MDM2 inhibitor and p53 activator, idasanutlin, enhanced CLM cytotoxicity
DNA damage response is considered an important strategy to enhance tumour cell killing caused by radiotherapy
biomarkers and therapeutic targets informing precision medicine strategies for PBT are mostly missing
resistance mechanisms to GO/InO remain incompletely understood
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.